Harnessing A20 to Modulate Immunity in Lung Cancer

Lung cancer is the leading cause of cancer-related deaths worldwide, with lung adenocarcinoma being the most common subtype. Around one third of these cases carry a mutation in the so-called K-RAS gene, which promotes tumor growth. These tumors often develop in chronically inflamed tissue frequently caused by heavy smoking a condition that further fuels cancer progression. This research project focuses on a protein called A20, which acts as a natural brake on inflammation in the body. Previous studies have shown that lung cancer cells with low A20 levels grow more aggressively and are less responsive to immune cells. Surprisingly, it was also found that a slight reduction of A20 not in the tumor cells themselves, but in the surrounding immune cells, can actually strengthen the immune system and slow down tumor growth. The aim of this project is to better understand this paradoxical effect. To this end, researchers will use innovative mouse models with specific genetic modifications. They aim to unravel how A20 influences the interaction between tumor cells and the immune system, and whether targeted modulation of A20 can enhance the effectiveness of immunotherapies a promising treatment option and often the only hope for patients with K-RAS mutations. Another exciting aspect of this project is that some individuals carry genetic variants of the gene encoding A20 that naturally reduce its expression. This study could help explain why certain patients respond better to immunotherapy than others. In the long term, the goal is to develop new therapeutic strategies that strengthen the bodys own immune response against lung cancer. The findings may be relevant not only for lung cancer, but also for other types of cancer with similar inflammation-driven mechanisms.